Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG

2020 Joyner, 2020, Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience, medRxiv Salazar, 2020, Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality, Am J Pathol, 190, 2290, 10.1016/j.ajpath.2020.08.001 Klassen, 2020, Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy, medRxiv Salazar, 2020, Relationship between anti-spike protein antibody titers and SARS-CoV-2 in vitro virus neutralization in convalescent plasma, bioRxiv Salazar, 2020, Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma, Am J Pathol, 190, 1680, 10.1016/j.ajpath.2020.05.014 Salazar, 2020, Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor binding domain IgG correlate with virus neutralization, J Clin Invest, 130, 6728, 10.1172/JCI141206 Barone, 2020, Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design, Transfusion, 60, 1123, 10.1111/trf.15843 Liu, 2020, Convalescent plasma treatment of severe COVID-19: a matched control study, Nat Med, 26, 1708, 10.1038/s41591-020-1088-9 Rosenbaum, 1983, The central role of the propensity score in observational studies for causal effects, Biometrika, 70, 41, 10.1093/biomet/70.1.41 Hastie, 2015 Lasso, 2020 Youden, 1950, Index for rating diagnostic tests, Cancer, 3, 32, 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3 Eckhardt, 2020, Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial, Trials, 21, 499, 10.1186/s13063-020-04422-y Gharbharan, 2020, Convalescent plasma for COVID-19: a randomized clinical trial, medRxiv Hegerova, 2020, Use of convalescent plasma in hospitalized patients with Covid-19: case series, Blood, 136, 759, 10.1182/blood.2020006964 Li, 2020, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial, JAMA, 324, 460, 10.1001/jama.2020.10044 Agarwal, 2020, Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial), BMJ, 371, m3939, 10.1136/bmj.m3939 Avendano-Sola, 2020, Convalescent plasma for COVID-19: a multicenter, randomized clinical trial, medRxiv Balcells, 2020, Early anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized phase II clinical trial, medRxiv Bohn, 2020, Pathophysiology of COVID-19: mechanisms underlying disease severity and progression, Physiology (Bethesda), 35, 288 Casadevall, 2020, The convalescent sera option for containing COVID-19, J Clin Invest, 130, 1545, 10.1172/JCI138003